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SHORT COMMUNICATION
Megalin in normal tissues and carcinoma cells
carries oligo/poly a2,8 deaminoneuraminic acid as a
unique posttranslational modification
Martin Ziak, Mirjam Meier and Jürgen Roth*
Division of Cell and Molecular Pathology, Department of Pathology, University of Zürich, CH-8091 Zürich, Switzerland
In rat kidney, megalin, a member of the low density lipoprotein receptor gene family, is the sole glycoprotein which carries
oligo/poly a2,8 deaminoneuraminic acid (KDN) as a posttranslational modification. We have investigated immunoprecipi-
tated megalin from rat brain, lung and placenta, mouse yolk sac carcinoma and megalin synthesizing carcinoma cell lines,
for presence of this unique glycan structure. Our immunoblot analysis revealed the presence of oligo/poly a2,8 KDN on
megalin in all the studied normal tissues and carcinoma cells. Furthermore, it is demonstrated to be part of oligosaccharides
O-glycosidically linked to megalin.
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Introduction
In previous studies, we demonstrated the presence of
oligo/poly a2,8 linked deaminoneuraminic acid (oligo/poly
a2,8 KDN) in various embryonic, postnatal developing and
adult mammalian tissues by immunohistochemistry and
immunoblot analysis [1,2] with the use of the monoclonal
antibody mAb.kdn8kdn [3]. The existence of KDN in mam-
malian tissues was furthermore confirmed by gas liquid
chromatography analysis [1], and a sensitive fluorescent
probe for HPLC [4] detection of KDN in tissues [5]. West-
ern blot analysis of extracts of various rat tissues revealed
the presence of a single reactive band in each tissue studied.
The oligo/poly a2,8 KDN was found on a single 150 kDa
glycoprotein except for a single .350 kDa glycoprotein in
kidney [1,2].
Recently, we isolated and purified the oligo/poly a2,8
KDN bearing glycoprotein from rat kidney [6] and identi-
fied it as being megalin, a member of the low-density lipo-
protein receptor gene family [7]. The presence of oligo/poly
a2,8 KDN on kidney megalin was confirmed by combined
immunoprecipitation / immunoblot analysis and on RAP-
affinity purified megalin. Further supporting evidence was
obtained by immunoelectron microscopy revealing an
identical subcellular distribution of oligo/poly a2,8 KDN
and megalin in rat kidney proximal tubules [6].
Megalin represents a major membrane protein of kidney
proximal tubules but is additionally found in rat lung, cho-
roid plexus and microvasculatur of brain, placenta, yolk sac
epithelia, ciliary epithelium of the eye, parathyroid as well
as inner ear [8]. Furthermore, by immunoblotting megalin
was demonstrated in mouse F9 teratocarcinoma cells [9]
and L2 rat yolk sac carcinoma cells [10].
Here, we report that megalin from various normal rat
tissues, carcinoma tissue and carcinoma cell lines carries
oligo/poly a2,8 KDN which is part of O-glycosidically
linked oligosaccharides.
Materials and methods
Materials
For the detection of oligo/poly a2,8 KDN, purified IgM of
the mouse monoclonal antibody mAb.kdn8kdn was used
[3]. The hybridoma cell line 2G-5 [3] was kindly supplied by
Dr. Ken Kitajima (University of Nagoya, Nagoya Japan).
Polyclonal antibodies against purified rat kidney megalin
were raised in rabbits as described previously [11] and IgG
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fractions prepared using Protein A Sepharose CL-4B
(Pharmacia, Uppsala, Sweden). Alkaline phosphatase-con-
jugated donkey anti-mouse IgM (affinity-purified) was
purchased from Jackson ImmunoResearch Laboratories,
Inc. (West Grove, PA, USA) and frozen rat tissues from Pel
Freez Biologicals (Rogers, AR, USA). Mouse yolk sac tu-
mor tissue and the L2 cell line were kindly supplied by Dr.
Ulla Wewer (University Institute of Pathological Anatomy,
Copenhagen, Denmark). Mouse F9 teratocarcinoma cells
were obtained from the American Type Culture Collection
(Rockville, MD). Protease inhibitor cocktail tablets, recom-
binant N-Glycosidase F and digoxigenin-conjugated Con-
canavalin A were from Boehringer (Mannheim, Germany).
Sephacryl S-400, XK 16/100 column were purchased from
Pharmacia (Uppsala, Sweden). All other reagents were of
analytical grade and purchased from Fluka (Buchs, Swit-
zerland).
Cell cultures
L2 cells were grown in Dulbecco’s modified Eagle’s me-
dium (DMEM) supplemented with high glucose and 10%
fetal calf serum at 378C in a humid atmosphere containing
5% CO2. Mouse F9 teratocarcinoma cells were cultured in
gelatin coated (0.1%) flasks in DMEM with high glucose
and 15% fetal calf serum. To induce differentiation, F9 cells
were incubated for 72 hours with 1 lM retinoic acid and 1
mM dibutyryl cyclic AMP.
Megalin immunoprecipitation
Protein A Sepharose CL-4B was incubated with PBS con-
taining 1% BSA and 0.05% of Triton X-100 and Tween 20
for 1 h at 48C, followed by incubation with anti-megalin
antibodies for 18 h at 48C. Rat kidney (0.7 g), lung (4.2 g),
brain (25 g), placenta (4.2g), mouse yolk sac carcinoma
tissue (4.2 g) and pellets of L2 and F9 cells (200 lg each)
were homogenized in PBS containing protease inhibitors
and Triton X-100 (final concentration 1%). After 60 min on
ice, the homogenate was centrifuged at 100,000 3 g for 60
min. The soluble extract was incubated with the anti-
megalin / Protein A Sepharose CL-4B overnight at 48C.
Following two washes with PBS containing 0.1% Triton
X-100, the Protein A Sepharose CL-4B was pelleted,
placed in SDS-PAGE sample buffer and heated. The super-
natant was analyzed by SDS-PAGE and Western blotting
using anti-oligo/poly a2,8 KDN or anti-megalin antibodies
as described previously [6].
Partial purification of megalin from mouse yolk sac
carcinoma tissue
A mouse yolk sac carcinoma tissue homogenate was ap-
plied onto a XK 16/100 gel filtration column packed with
Sephacryl S-400. Fractions, immunoreactive for oligo/poly
a2,8 KDN were pooled and used for Western blot and
lectin blot analysis.
b-elimination, N-Glycosidase F treatment and
lectin blotting
For b-elimination, PVDF strips containing partially puri-
fied megalin from yolk sac carcinoma tissue were incu-
bated with 0.1 N sodium hydroxide for 24 h at 378C. As
control, strips were incubated with PBS under the same
conditions as described above. For N-Glycosidase F treat-
ment, nitrocellulose strips with megalin were blocked with
1% BSA in 50 mM sodium acetate buffer (pH 5.5) fol-
lowed by incubation with 5 U of N-Glycosidase F for 16 h
at 378C. For lectin blotting, strips were incubated with
digoxigenin-conjugated Concanavalin A for 1 h followed
by alkaline phosphatase-conjugated polyclonal sheep anti-
digoxigenin Fab9 fragments (150 U/ml). Color reaction was
performed using nitroblue tetrazolium/BCIP-phosphate as
substrates.
Results and discussion
In our previous studies [6] the .350 kDa oligo/poly a2,8
KDN bearing glycoprotein from rat kidney was identified
as being megalin. Megalin is the most abundant mem-
brane protein in proximal tubules of rat kidney but it is
also expressed in other specialized epithelia [8] albeit at
much lower levels. Immunoprecipitated megalin from rat
lung, brain and placenta, from mouse yolk sac carcinoma
tissue as well as L2 cells and from mouse F9 teratocarci-
noma cells, induced to differentiate (data not shown) ex-
hibited  immunoreactivity for oligo/poly a2,8 KDN (Fig.
1). Thus, megalin present in these normal rat tissues and
in carcinoma cells carries oligo/poly a2,8 KDN as a unique
posttranslational modification. These findings on megalin
are similar to those for a 150 kDa glycoprotein in lung
which also carries oligo/poly a2,8 KDN both in normal
human and rat embryonic and postnatal lung and in hu-
man lung carcinomas [2]. Furthermore, KDN has been de-
tected in both normal human ovary and ovarian
carcinoma cells but no data have been reported regarding
its protein carrier [12].
b-elimination on stripes containing partially purified
megalin from mouse yolk sac tissue resulted in the absence
in immunoreactivity for oligo/poly a2,8 KDN. In contrast
N-glycosidically linked oligosaccharides on megalin are not
affected by this treatment as demonstrated by the reactiv-
ity with Conconavalin A (Fig. 2). Furthermore, N-Glycosi-
dase F treatment increased the immunoreactivity for
oligo/poly a2,8 KDN (Figure 2) indicating that oligo/poly
a2,8 KDN is part of O-glycosidically linked oligosaccha-
rides on megalin from mouse yolk sac carcinoma tissue.
These  data are in agreement with previously described
results obtained from purified rat kidney megalin [6].
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Megalin has been found to bind a number of different
ligands (for a review see [13]) in vitro. What may be a
possible function of oligo/poly a2,8 KDN on megalin? Due
to its localization in clathtrin-coated pits megalin was sug-
gested to act as an endocytic receptor in kidney. Dependent
on the organ localization of megalin and the composition
of the surrounding fluids it can be anticipated that the
nature of the ligands will vary from one organ to another.
For  example, in proximal tubules it  was  suggested that
megalin is involved in the reabsorption of filtered proteins
[14] and Ca21-ions [15]. In type II pneumocytes, megalin
seems to be responsible for the clearance of protease /
protease inhibitor complexes [16,17] from the alveolar
space [18]. Charge interactions between negatively charged
complement-type repeats and basic regions of the ligands
seems to be important for receptor / ligand interaction.
Furthermore, megalin is not only a Ca21 binding protein
but Ca21-ions are essential for ligand binding. In vitro
oligo/poly a2,8 KDN binds Ca21-ions highly preferentially
[19]. Therefore, we speculate that the polyanionic nature of
oligo/poly a2,8 KDN together with the negatively charged
complement-type repeats may be important for ligand
binding  to  megalin  and for the receptor activity in  the
various tissues. Studies are in progress to clarify this pro-
posal.
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